ArticleOncotarget2018

High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis.

Thenappan Chandrasekar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.